Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Dr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
In skin of color, psoriasis can be tough to spot, and it carries a broader differential diagnosis. Darker-skinned patients may not know that they can develop psoriasis, or the importance of seeking treatment early.
Stepwise introduction of egg (starting with a low dose, which is then increased), along with aggressive treatment of atopic dermatitis (AD), is a safe and effective way to prevent hen’s egg allergy in high-risk infants, a study in Japan showed.
A healthy 12-year-old boy with eczema shows up at the office with an incredibly itchy rash on his legs that has exploded over the last 48 hours. He has a history of dry skin to which his mother regularly applies various moisturizers, including calendula oil.
A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.